
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZER1 (zyg-11 related cell cycle regulator) encodes a subunit of an E3 ubiquitin ligase complex that may participate in regulation of meiosis. The protein contains multiple leucine-rich repeat motifs, which may contribute to its interactions within ubiquitin-dependent regulatory complexes. ZER1 is relevant to studies of E3 ubiquitin ligase function, protein turnover, cell-cycle regulation, and meiotic cellular processes.
JAR is a human choriocarcinoma cell line established from a trophoblastic tumor of the placenta of a 24-year-old woman. The cell line originates from a male fetus and represents a trophoblast-derived tumor model. JAR is used for studies of placental biology, trophoblast differentiation, and mechanisms involved in gestational cancers.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_001375956
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?